Compare

Almirall, S.A./€ALM

1D1W1M3M6MYTD1Y5YMAX

About Almirall, S.A.

Almirall, S.A. is a pharmaceutical company headquartered in Barcelona, Spain. It specializes in the development and commercialization of proprietary medicines, with a focus on dermatology and other specialist-driven therapeutic areas. Almirall's notable products target conditions such as psoriasis, atopic dermatitis, and actinic keratosis. Founded in 1943, the company has expanded its geographical footprint across Europe and North America through strategic acquisitions and partnerships. Almirall emphasizes research and development, maintaining a pipeline of innovative treatments aimed at unmet medical needs. Its strategic positioning is reinforced by collaborations with healthcare professionals and institutions to enhance patient care.
Ticker
€ALM
Sector
Health
Primary listing
BME
Employees
2,097
Headquarters
Barcelona, Spain
Website
www.almirall.com

Almirall, S.A. Metrics

BasicAdvanced
€2.3B
38.33
€0.28
0.18
€0.15
1.43%

What the Analysts think about Almirall, S.A.

Analyst ratings (Buy, Hold, Sell) for Almirall, S.A. stock.
Analyst projections of the future price of Almirall, S.A. stock.

Bulls say / Bears say

First-half 2026 sales rose 7.5% to €602.7 million and EBITDA climbed 23.7% to €150.7 million. Almirall kept its full-year sales-growth and EBITDA guidance unchanged, signalling confidence in execution. (Almirall)
European dermatology sales grew 18.1% in the first half, led by Ebglyss, up 88.2%, and Ilumetri, up 10.5%. Continued uptake of these biologics gives the company strong near-term growth drivers. (Almirall)
New extension-study results showed sustained skin and itch responses with lebrikizumab through up to five years, strengthening the evidence behind Ebglyss. The EMA has also accepted Almirall’s filing to extend its use to younger children in Europe. (BioSpace, BioSpace)
First-quarter net profit fell 29.2% to €15.3 million and EBITDA declined 4.8%. OTC and general-medicine revenue dropped 14.3%, showing that weakness outside the growth dermatology business can weigh on results. (ARA)
Almirall reported softer German sales after a pricing adjustment and said Germany’s 2027 drug-pricing reform was unfavourable for the industry, with details still unresolved. Lower prices or reimbursement changes could limit growth in a key launch market. (Yahoo Finance)
Some of the first-half margin improvement came from the Actithiol divestment, while management expected gross margin to normalise and royalty costs to rise. It also flagged higher R&D and promotional spending in the second half, which could make the 25% EBITDA margin harder to sustain. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.

Almirall, S.A. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Almirall, S.A. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Almirall, S.A.

AllEURUSDGBP
Funds
Fund name
Fund size
€ALM weighting
Xtrackers Spain€XESD
€282M0.10%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.06%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.06%
iShares MSCI World Small Cap£WLDS
$9B0.01%
iShares MSCI World Small Cap€IUSN
$9B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.